Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma

British Journal of Dermatology

Volumn 153, Issue 5, 2005, Pages 925-931

  Richtig, Erika ^a   Ludwig, R ^a   Kerl, H ^a   Smolle, J ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Chemotherapy; Local treatment options; Metastatic melanoma; Organ specific response rate; Treatment specific response rate

Indexed keywords

CARBOPLATIN; DACARBAZINE; FOTEMUSTINE; TEMOZOLOMIDE; VINDESINE;

ADRENAL METASTASIS; ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG RESPONSE; DRUG SPECIFICITY; FEMALE; GAMMA KNIFE RADIOSURGERY; HUMAN; HYPERTHERMIC THERAPY; KIDNEY METASTASIS; LIVER METASTASIS; LOCAL THERAPY; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM METASTASIS; MELANOMA; MONOTHERAPY; MUSCLE METASTASIS; PANCREAS CANCER; PERITONEUM METASTASIS; PLEURA METASTASIS; PREDICTION; PRIORITY JOURNAL; REMISSION; RISK ASSESSMENT; SKIN METASTASIS; SOFT TISSUE METASTASIS; SPINAL CORD METASTASIS; SPLEEN CANCER; STATISTICAL SIGNIFICANCE; STOMACH CANCER; SURVIVAL TIME; SYSTEMIC THERAPY; THYROID CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 27544488784     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06796.x     Document Type: Article

References (38)

1. Meier F, Will S, Ellwanger U et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147:62-70.
2. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group Trials. J Clin Oncol 2000; 18:3782-93.
3. Sirott MN, Bajorin DF, Wong GYC et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993; 72:3091-8.
4. Balch CM, Soong SJ, Murad TM et al. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1983; 1:126-34.
5. Balch CM, Houghton AN. Diagnosis of metastatic melanoma at distant sites. In: Cutaneous Melanoma (Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S, eds), 2nd edn. Philadelphia: Lippincott, 1992; 439-67.
6. Kefford RF. Management of the patient with advanced melanoma. In: Textbook of Melanoma (Thompson JF, Morton DL, Kroon Bin BR, eds). London: Dunitz, 2004; 535-46.
7. Middleton MR, Grob JJ, Aaronson N et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-66.
8. Frick S, Lischner S, Rosien F et al. Temozolomid als Therapieoption bei Patienten mit fernmetastasiertem Melanom und ungünstiger Prognose. Hautarzt 2002; 53:659-65.
9. Becker JC, Kämpgen E, Bröcker EB. Klassische Chemotherapie des metastasierenden Melanoms. Z Hautkr 2000; 9:553-8.
10. Wendtner CM, Hallek M, Schmid-Wendtner MH. Medikamentöse Therapie bei Fernmetastasierung. In: Empfehlungen zur Diagnostik, Therapie und Nachsorge maligner Melanome, Tumorzentrum München (Volkenandt M, Plewig G, eds), 5th edn. Munich: Zugschwerdt, 2000; 65-71.
11. Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alpha-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9:1403-8.
12. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:2745-51.
13. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000; 19:21-34.
14. Tilgen W, Uhl K, Bröcker EB. Palliative Therapie des malignen Melanoms. In: Dermatologische Onkologie (Garbe C, Dummer R, Kaufmann R, Tilgen W, eds). Berlin: Springer-Verlag, 1997; 369-86.
15. Hwu WJ. New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide. Oncology 2000; 12 (Suppl. 13):S25-8.
16. Bafaloukos D, Gogas H, Georgoulias V et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 2002; 20:420-5.
17. Houghton AN, Legha S, Bajorin DF. Chemotherapy for metastatic melanoma. In: Cutaneous Melanoma (Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S, eds), 2nd edn. Philadelphia: Lippincott, 1992; 498-508.
18. Khayat D, Meric JB, Rixe O. Systemic chemotherapy and biochemotherapy for non-resected and metastatic melanoma. In: Textbook of Melanoma (Thompson JF, Morton DL, Kroon Bin BR, eds). London: Dunitz, 2004; 586-601.
19. Walsh P, Gibbs P, Gonzalez R. Newer strategies for effective evaluation of primary melanoma and treatment of stage III and IV disease. J Am Acad Dermatol 2000; 42:480-9.
20. Balch CM, Buzaid A, Atkins M et al. A new American Joint Committee on Cancer Staging System for Cutaneous Melanoma. Cancer 2000; 88:1484-91.
21. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181:193-201.
22. Garbe C, Schaumburg-Lever G. Klinik und Histologie des malignen Melanoms. In: Dermatologische Onkologie (Garbe C, Dummer R, Kaufmann R, Tilgen W, eds). Berlin: Springer-Verlag, 1997; 247-70.
23. Houghton AN, Balch CM. Treatment of advanced melanoma. In: Cutaneous Melanoma (Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S, eds), 2nd edn. Philadelphia: Lippincott, 1992; 468-97.
24. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. Int J Radiat Oncol Biol Phys 1999; 44:607-18.
25. Kirova YM, Chen J, Rabarijaona LI et al. Radiotherapy as palliative treatment for metastatic melanoma. Melanoma Res 1999; 9:611-13.
26. Douglas JG, Margolin K. The treatment of brain metastases from malignant melanoma. Semin Oncol 2002; 29:518-24.
27. Gonzalez Gonzalez D, van Dijk JD, Blank LE, Rumke P. Combined treatment with radiation and hyperthermia in metastatic malignant melanoma. Radiother Oncol 1986; 6:105-13.
28. Overgaard J, Gonzalez Gonzalez D, Hulshof MCCM et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. Lancet 1995; 345:540-3.
29. Richtig E, Hoff M, Rehak P et al. Efficacy of superficial and deep regional hyperthermia combined with systemic chemotherapy and radiotherapy in metastatic melanoma. J Dtsch Dermatol Ges 2003; 1:635-42.
30. Falk MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia 2001; 17:1-18.
31. Karrer S, Szeimies RM, Hohenleutner U, Landthaler M. Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy. Am J Clin Dermatol 2001; 2:229-37.
32. Oratz R, Hauschild A, Sebastian G et al. Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma. Melanoma Res 2003; 13:59-66.
33. Wolf IH, Smolle J, Binder B et al. Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 2003; 139:273-6.
34. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-16.
35. Padhani AR, Ollivier L. The RECIST criteria: implications for diagnostic radiologists. Br J Radiol 2001; 74:983-6.
36. Fritsch P, Zelger B, Sepp N. Tumoren der Haut. In: Dermatologie Venerologie (Fritsch P, ed.), 2nd edn. Berlin: Springer-Verlag, 2004; 585-697.
37. Bleehen NM, Newlands ES, Lee SM et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995; 13:910-13.
38. Rixe O, Borel C, Paraiso D et al. Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients. Melanoma Res 1995; 5:419-24.